Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease

Coronary Artery Disease

Volumn 7, Issue 11, 1996, Pages 843-850

  Kontopoulos, Athanasios G ^a   Athyros, Vasilios G ^a,d   Papageorgiou, Athanasios A ^a   Hatzikonstandinou, Haris A ^b   Mayroudi, Melachrini C ^a   Boudoulas, Harisios ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c OHIO STATE UNIVERSITY   (United States)

^d NONE   (Greece)

Author keywords

Ciprofibrate; Familial combined hyperlipidaemia; Low density lipoprotein pattern; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CIPROFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030463802     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199611000-00009     Document Type: Article

References (43)

1. Grundy SM, Chait A, Brunzell JD: Familial combined hyperlipidemia work-shop. Arteriosclerosis 1987, 7:203-207.
2. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, et al.: Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994, 14:1569-1575.
3. de Oya M, Alvarez-Sala LA, Mata P, Alonzo R: The role of cholesterol in the pathogenesis of atherosclerosis. Primary and secondary causes of hyperlipidemia. In Molecular Cell Biology of Cardiovascular Diseases. Edited by Diez J, Dzau VJ, Ferrari R, Frohlich ED. Madrid: Mosby/Doyma Libros; 1995:149-179.
4. Dejager S, Bruckert E, Chapman MJ: Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993, 34:295-308.
5. Thomson GR: A Handbook of Hyperlipidaemia. London: Current Science; 1990.
6. East C, Bilheimer DW, Grundy SM: Combination drug therapy for familial combined hyperlipidaemia. Ann Intern Med 1988, 109:25-32.
7. The Scandinavian Simvastatin Survival Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
8. Oro L, Carson LA, Olsson A, Poole PH: Long term effect of ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res 1992, 51:229-243.
9. Gaw A, Packard CJ, Caslake MJ, Griffin BA, Lindsay GM, Thomson J, et al.: Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994, 108:137-148.
10. Bruckert E, Dejager S, Chapman MJ: Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993, 100:91-102.
11. Bredie SJ, de Bruin TW, Demacker PN, Kastelem JJ, Stalenhoel AF: Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995, 75:348-353.
12. Hokanson JE, Austin MA, Zambon A, Brunzell JD: Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993, 13:427-434.
13. Athyros V, Papageorgiou A, Hagikonstantinou H, Papadopoulos G, Zamboulis C, Kontopoulos A: Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidaemia. Drug Invest 1994, 7:134-142.
14. Athyros V, Papageorgiou A, Basagiannis E, Lafaras C, Kontopoulos A: Pilot study of the effect on myocardial infarction risk profile of the simvastatin-ciprofibrate combination in patients with refractory familial combined hyperlipidaemia. Clin Drug Invest 1996, 11:196-204.
15. International Committee for the Evaluation of Hypertriglyceridemia as a Vascular Risk Factor: Hyperglyceridemias: risks and management Am J Cardiol 1992, 68:1A-42A.
16. Lipid Research Clinic Study Group: Population Study Data Book. Volume I: The LRC Prevalence Study. Bethesda: National Institutes of Health; 1980.
17. Assmann G, Schulte H: Relation of high-density lipoprotein and triglycerides to incidence of atherosclerotic coronary artery disease (the PRO.CA.M experience). Am J Cardiol 1992, 70:733-737.
18. Demacker PNM, Hijmans AG, Vos-Janssen HE, van't Laar A, Jansen AP: A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 1980, 26:1775-1779.
19. de Graaf J, Hak Lemmers DW, Hectors MP, Demacker PNM, Hendriks JCM, Stalenhoef AFH: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991, 11:298-306.
20. de Graaf J, Swinkels DW, de Haan AF, Demacker PNM, Stalenhoef AFH: Both inherited susceptibility and environmental exposure determine the low density lipoprotein subfraction pattern distribution in healthy Dutch families. Am J Hum Genet 1992, 51:1295-1310.
21. Tobert JA: Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988, 62:28J-34J.
22. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low density lipoprotein subclass patters and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
23. Tornvall P, Båvenholm P, Landou C, de Faire U, Hamsten A: Relation of plasma levels of apoprotein B-containing lipoproteins angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993, 88:2180-2189.
24. Chait A, Brazg RL, Krauss RM: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993, 94:350-356.
25. Assmann G, Schulte H: Identification of individuals at high risk for myocardial infarction. Atherosclerosis 1994, 110(suppl A):11S-21S.
26. Heinrich J, Assmann G: Fibrinogen and cardiovascular risk. J Carodiovasc Risk 1995, 2:197-205.
27. Pazzucconi F, Franceschini G, Gianfranceschi G, Brambilla E, Sirtori CR: Lipoprotein structure in male subjects during in vivo lipolysis: effect of an anti-lipolytic treatment with acipimox. J Lipid Res 1993, 34:1465-1472.
28. Zambon S, Cortella A, Sartore G, Baldo Enzi G, Manzato E, Crepaldi G: Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol 1994, 46:221-224.
29. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al.: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994, 106:241-253.
30. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71-75.
31. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, et al.: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993, 94:13-20.
32. Yeshurum D, Abukarshm R, Elias N, Lanir A, Naschitz JE: Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Ther 1993, 15:335-363.
33. Feher MD, Foxton J, Banks D, Lant AF, Wray R: Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995, 74:14-17.
34. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K. et al.: Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994, 15:255-269.
35. Simons LA, for the Principal Investigators: Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. Clin Cardiol 1993, 16:317-322.
36. Mol MJ, Stuyt PM, Demacker PN, Stalenhoef AF: The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia. Neth J Med 1990, 36:182-190.
37. Shepherd J: Mechanism of action of fibrates. Postgrad Med J 1993. 69(suppl A):34S-41S.
38. Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, et al.: Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993, 13:702-711.
39. Genest J Jr, Cohn JS: Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol 1995, 76:8A-20A.
40. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, et al.: Effects of simvastatin on apoprotein B metabolism and LDL subfraction distribution. Arterioscler Thromb 1993, 13:170-189.
41. Willis RA, Folkers K, Tucker JL, Ye C-Q, Xia L-J, Tamagawa H: Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990, 87:8928-8930.
42. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ: Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993, 46:1055-1057.
43. Laaksonen R, Jokelamen K, Sahi T, Tikkanen MJ, Himberg JJ: Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995, 57:62-66.